je.st
news
Tag: medicines
MSD Animal Health Receives Positive Final Opinion from European Medicines Agency for BRAVECTO (fluralaner) Spot-On for Cats and Dogs
2016-03-22 09:00:00| Merck.com - Corporate News
Dateline City: MADISON, N.J. Only Spot-On Treatment for Fleas and Ticks Effective For 12 Weeks MADISON, N.J.--(BUSINESS WIRE)--MSD Animal Health (known as Merck Animal Health in the United States and Canada) today announced that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency has adopted a positive final opinion, recommending the granting of a marketing authorization for the veterinary medicinal product BRAVECTO (fluralaner) Spot-On for both cats and dogs. Language: English Contact: MSD Animal HealthMedia:Amy Firsching, +1-908-473-6357amy.firsching@merck.comorPam Eisele, +1-908-423-5042pamela_eisele@merck.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: health
final
positive
opinion
Animal Medicines Sector Responds to O’Neill Antimicrobials in Agriculture Report
2015-12-31 01:00:00| ThePigSite - Industry News
UK - The UK, European and global animal medicines sector associations have joined forces to respond to Lord O’Neill’s recent Report on Antimicrobials in Agriculture, through a letter and expert critique of his Report.
Tags: report
sector
animal
agriculture
Alkermes Announces Achievement Of Milestones For CNS Medicines In Proprietary Product And Pipeline Portfolio
2015-12-21 04:02:36| dairynetwork News Articles
Alkermes plc recentlyannounced new developments and milestones related to its proprietary product and late-stage pipeline portfolio of medicines for the treatment of central nervous system (CNS) diseases
Tags: product
portfolio
achievement
announces
GSK buys HIV medicines for $1.4bn
2015-12-18 14:06:55| BBC News | Business | UK Edition
GlaxoSmithKline ends a frenetic week for the pharmaceutical sector with a $1.4bn takeover of HIV drug development assets from Bristol-Myers Squibb.
Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir
2015-12-18 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has responded to the companys marketing authorization application (MAA) for elbasvir/grazoprevir (50mg/100mg), which is under review for the treatment of adult patients with chronic hepatitis C (HCV) infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
marketing
update
agency
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] next »